ROVI has obtained the best ESG score from among the 458 companies evaluated in its pharmaceutical subindustry category.
Mon, 01/08/2022 - 00:00
2 minROVI has obtained the best ESG score from among the 458 companies evaluated in its pharmaceutical subindustry category.
6s3a6968_1.jpg
ROVI tops the Sustainalytics sustainability ranking for the pharmaceutical subindustry worldwide
Madrid, 1 August, 2022
In July 2022, the Environmental, Social and Governance (ESG) aspects of ROVI were evaluated by Sustainalytics, a leading independent ESG and corporate governance research, ratings and analytics firm that supports investors around the world with the development and implementation of responsible investment strategies. ROVI obtained the best rating from among the 458 companies evaluated in the pharmaceutical subindustry. This year, ROVI has obtained an ESG risk rating of 17.3 points, thus continuing in a low-risk position (between 10 and 20 points).
This rating shows an improvement of 1.1 points on last year’s rating (18.4 points) and places ROVI at the top of the ranking in its pharmaceutical subindustry worldwide. Among the 970 companies in the industry, which includes biotechnology companies, pharmaceutical laboratories and medical device companies, ROVI is in 22nd place.
Among the actions that have allowed ROVI to improve its rating in 2022, its commitment to the environment may be highlighted, due to the implementation of greenhouse gas reduction programmes and the use of renewable energy. Additionally, ROVI has been considered the sector leader in aspects such as the oversight of material ESG issues by senior management and its anti-corruption / anti-bribery policy in the Corporate Governance space, together with, in the Social area, the implementation of a sound equality and non-discrimination policy.
ROVI’s rating may be consulted on the following link: https://www.rovi.es/sites/default/files/Laboratorios_Farmace%C3%BAticos_Rovi_SA_RiskRatingsSummaryRe...
About ROVI
ROVI is a pan-European pharmaceutical company specialising and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, already marketed in 89 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its enoxaparin biosimilar, developed in-house, in Europe and it is now marketed in 38 countries. ROVI continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. For more information, please visit www.rovi.es.